Bio-Techne - Public Comps and Valuation Multiples

Bio-Techne Overview

About Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Founded

1976

HQ

Employees

3.1K+

Website

bio-techne.com

Sectors

Laboratory Services
Pharma Diagnostics & Analytics
BioTech

Financials

LTM Revenue $1.2B

LTM EBITDA $430M

EV

$9.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Bio-Techne Financials

As of September 2025, Bio-Techne reported last 12-month revenue of $1.2B and EBITDA of $430M.

In the same period, Bio-Techne generated $856M in LTM gross profit and $309M in net income.

See Bio-Techne valuation multiples based on analyst estimates

Bio-Techne P&L

In the most recent fiscal year, Bio-Techne reported revenue of $1.2B and EBITDA of $217M.

Bio-Techne expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Bio-Techne valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.2B	XXX	$1.2B	XXX	XXX	XXX
Gross Profit	$856M	XXX	$790M	XXX	XXX	XXX
Gross Margin	70%	XXX	65%	XXX	XXX	XXX
EBITDA	$430M	XXX	$217M	XXX	XXX	XXX
EBITDA Margin	35%	XXX	18%	XXX	XXX	XXX
EBIT	$389M	XXX	$243M	XXX	XXX	XXX
EBIT Margin	32%	XXX	20%	XXX	XXX	XXX
Net Profit	$309M	XXX	$73.4M	XXX	XXX	XXX
Net Margin	25%	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	XXX	$184M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Bio-Techne including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.2B. EBITDA for the last twelve months was $430M. In the most recent fiscal year, Bio-Techne achieved $1.2B in revenue and $217M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.2B	Analyst estimates available to subscribers	$1.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$856M	Analyst estimates available to subscribers	$790M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	69.8% gross margin	Analyst estimates available to subscribers	64.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$430M	Analyst estimates available to subscribers	$217M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	35.0% EBITDA margin	Analyst estimates available to subscribers	17.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$389M	Analyst estimates available to subscribers	$243M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	31.7% EBIT margin	Analyst estimates available to subscribers	19.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$309M	Analyst estimates available to subscribers	$73.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.2% net profit margin	Analyst estimates available to subscribers	6.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$184M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Bio-Techne

This financial data table provides comprehensive performance metrics for Bio-Techne, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Bio-Techne generated $1.2B in revenue over the last twelve months.
The company achieved $430M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $856M.
Net income over the last twelve months reached $309M.

Fiscal Year Performance

In the most recent fiscal year, Bio-Techne reported $1.2B in total revenue.
Fiscal year EBITDA was $217M.
The company maintained a gross profit margin of 64.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 17.8%.
Net profit margin reached 6.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Bio-Techne. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Bio-Techne Stock Performance

Bio-Techne has current market cap of $9.6B, and EV of $9.9B.

Market Cap Evolution

Bio-Techne Stock Data

As of October 17, 2025, Bio-Techne's stock price is $62.

See Bio-Techne trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$9.9B	$9.6B	XXX	XXX	XXX	XXX	$1.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Bio-Techne Valuation Multiples

Bio-Techne's trades at 8.3x EV/Revenue multiple, and 37.4x EV/EBITDA.

See valuation multiples for Bio-Techne and 15K+ public comps

Bio-Techne Financial Valuation Multiples

As of October 17, 2025, Bio-Techne has market cap of $9.6B and EV of $9.9B.

Equity research analysts estimate Bio-Techne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bio-Techne has a P/E ratio of 31.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$9.6B	XXX	$9.6B	XXX	XXX	XXX
EV (current)	$9.9B	XXX	$9.9B	XXX	XXX	XXX
EV/Revenue	8.1x	XXX	8.3x	XXX	XXX	XXX
EV/EBITDA	23.1x	XXX	37.4x	XXX	XXX	XXX
EV/EBIT	25.5x	XXX	40.5x	XXX	XXX	XXX
EV/Gross Profit	11.6x	XXX	n/a	XXX	XXX	XXX
P/E	31.2x	XXX	79.8x	XXX	XXX	XXX
EV/FCF	36.0x	XXX	40.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Bio-Techne Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Bio-Techne Margins & Growth Rates

Bio-Techne's last 12 month revenue growth is 4%

Bio-Techne's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Bio-Techne's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bio-Techne's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Bio-Techne and other 15K+ public comps

Bio-Techne Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	4%	XXX	4%	XXX	XXX	XXX
EBITDA Margin	35%	XXX	22%	XXX	XXX	XXX
EBITDA Growth	5%	XXX	32%	XXX	XXX	XXX
Rule of 40	26%	XXX	26%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	44%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	45%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial